Зиромин

Quick links

Choose a section

Quick links to important sections

Advertisements

Зиромин

Advertisements

Overview of Зиромин

What is Зиромин? (Azithromycin)

Property Description
Active Ingredient Azithromycin
Pharmacological Class Macrolide Antibiotic (Azalide Subclass)
Origin Semi-synthetic
Primary Forms Tablet, Oral Suspension, IV Solution
General Purpose Controlling bacterial infections

What Type of Medicine is Зиромин?

Зиромин is an antibacterial medication containing the active substance Azithromycin, a prescription drug used for its activity against various pathogens. It is classified as an antibiotic and belongs to the macrolide family. Azithromycin exerts its antimicrobial effects by targeting the bacterial ribosome, a mechanism specifically designed to act against microbial life.

The chemical structure of Azithromycin further designates it as an azalide, which is a semi-synthetic subclass derived from the older macrolide, Erythromycin. This specific structural modification allows Azithromycin to achieve high tissue penetration and maintain a long half-life. This extended effect is a distinguishing feature of the medication's pharmacological profile.


Composition and Available Forms of Azithromycin

The therapeutic effect of Зиромин is based on its active ingredient, Azithromycin (often present as Azithromycin Dihydrate). It is a single-entity product combined with standard pharmaceutical excipients. Зиромин is commonly available in an oral suspension form, which is suitable for both adults and pediatric patients who require liquid administration.

To accommodate different clinical needs and routes of administration, Azithromycin is produced in several dosage forms. These include solid tablets for oral use, aqueous oral suspension for liquid dosing, and sterile intravenous solution used when rapid systemic treatment is required. Azithromycin is used for its effectiveness against a broad array of bacterial infections.


What is the General Purpose of Azithromycin?

The general purpose of Зиромин is to control and eliminate the microbial cause of illness by exerting a bacteriostatic action against susceptible bacteria. It achieves this by selectively binding to internal bacterial structures to block the synthesis of essential proteins. By halting the growth and replication of pathogens, Зиромин reduces the overall bacterial load, allowing the body's natural defenses to clear the remaining infection. This mechanism is the primary basis for its use in managing bacterial infections.

Regulatory References

  1. U.S. National Library of Medicine
Advertisements

What side effects are possible with Зиромин?

Possible side effects and safety information for Зиромин

This section outlines documented possible side effects and safety considerations for Зиромин, based on the established regulatory profile of macrolide antibiotics.

Common Adverse Reactions

The most frequently reported side effects are related to the gastrointestinal system. These typically include diarrhea, nausea, and abdominal pain.

Serious and Clinically Significant Safety Concerns

Macrolide antibiotics carry risks for serious, though rare, adverse reactions, and patients should be aware of the potential for:

  • Serious Allergic Reactions: Severe, life-threatening hypersensitivity reactions, including anaphylaxis and angioedema. Dermatologic events like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported.
  • Cardiovascular Risk: The drug is associated with QT interval prolongation, which can lead to a potentially fatal, irregular heart rhythm called Torsades de Pointes. Patients with pre-existing heart conditions, a history of arrhythmias, or those taking other QT-prolonging medicines are at higher risk.
  • Hepatotoxicity: Cases of abnormal liver function, cholestatic jaundice, and, in rare instances, fatal hepatic failure have been documented. The drug should be discontinued immediately if signs of liver dysfunction appear.
  • Gastrointestinal Complications: Clostridioides difficile-associated diarrhea (CDAD), which can range from mild to life-threatening colitis, may occur with use.

Population and Usage Precautions

Caution is warranted for specific patient groups and concomitant use of certain medications:

  • Cardiac Conditions: Use should be avoided or closely monitored in patients with known QT prolongation, uncorrected low potassium or magnesium levels, or significant bradycardia.
  • Liver Impairment: The drug is primarily eliminated by the liver, and caution is advised for individuals with significant hepatic disease.
  • Drug Interactions: Co-administration with certain medications, particularly ergot derivatives or drugs that prolong the QT interval, is contraindicated or requires careful assessment due to the potential for severe adverse events.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Зиромин (Azithromycin) carries the risk of severe clinical outcomes and necessitates immediate professional attention. Officially documented manifestations of overdosage are generally similar to the adverse reactions seen at normal therapeutic doses, primarily involving gastrointestinal symptoms such as nausea, vomiting, diarrhea, and stomach discomfort.


Required Emergency Actions

Government regulatory authorities mandate that immediate medical attention must be sought upon suspicion of overdosage. Emergency services or a poison control center should be contacted immediately, particularly if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.


Severe Risks and Management

The primary clinical concern in an overdose setting is the potential for life-threatening cardiotoxicity and hepatic failure. Regulatory documents highlight the risk of QT interval prolongation, which may lead to severe arrhythmias, including Torsades de pointes, and ultimately, cardiovascular death. Because no specific antidote is known, treatment is limited to the provision of general symptomatic and supportive measures and required monitoring.


Specific Considerations

Overdose management must account for patient-specific risks. Individuals with pre-existing risk factors—such as known QT prolongation or low blood levels of potassium or magnesium—are officially noted as more susceptible to severe cardiac effects. Women and elderly patients are documented as potentially demonstrating greater sensitivity to drug-related QT interval alteration, which requires special consideration.

Advertisements

Therapeutic Uses of Зиромин

What Зиромин Treats: Main Uses and Benefits

The primary role of Зиромин may be to provide therapeutic support for conditions related to certain bacteria, focusing on managing the infectious process and easing the resulting symptomatic burden across key body systems. The medication is commonly used to help manage various conditions characterized by bacterial presence, providing support that helps ease the overall symptom load. It is applied across domains where additional symptomatic support is needed to address symptoms that interfere with daily functioning.

It is commonly used across conditions presenting with acute episodes of infection, including bacterial bronchitis, pneumonia, acute otitis media (ear infection), certain skin and soft tissue infections (like cellulitis), and specific sexually transmitted infections (STIs). The medicine may assist with symptom clusters that may become intense, like fever, painful swallowing, and persistent cough, contributing to improved comfort during periods of heightened symptoms.

“The primary goal of this therapy is to offer supportive relief during periods of heightened symptoms, helping to ease the overall symptomatic burden.”

Quick Fact: Benefit – Easing Acute Pain and Strain The medication is relevant in contexts involving inflammatory or irritative processes by easing manifestations like localized swelling, redness, and tenderness, which may assist with managing symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview of Azithromycin
Advertisements

Eligibility and Restrictions for Use

Regulatory documents establish strict criteria for who can and cannot use this medicine (azithromycin).

Populations for Whom Use is Prohibited (Contraindicated)

Classification Basis for Exclusion
Hypersensitivity Known allergy to azithromycin itself, or to any macrolide or ketolide antibacterial drug.
Prior Hepatic Injury History of cholestatic jaundice or hepatic dysfunction specifically associated with previous use of azithromycin.

Use Requires Special Caution or is Not Recommended

Patient Group or Condition Regulatory Constraint
Age Restriction (Pediatric) Safety and effectiveness are not established for treating patients under 6 months of age. Not established for pharyngitis/tonsillitis in those under 2 years.
Cardiac Risk Factors Use requires caution in patients with existing QT interval prolongation, a history of a specific abnormal heart rhythm ( Torsades de Pointes), or uncorrected low potassium ( hypokalemia) or magnesium ( hypomagnesemia). Elderly patients may be at increased risk.
Severe Illness Use is not recommended for patients with moderate to severe illness or risk factors (e.g., suspected bacteremia, nosocomial infection) that make them inappropriate for oral treatment of community-acquired pneumonia.
Pre-existing Conditions Caution is advised for patients with severe renal impairment ( GFR < 10 mL/min) or Myasthenia Gravis (a condition it may exacerbate).

Regulatory agencies advise that the medicine be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interaction data documented in official regulatory sources for Azithromycin.

Classification Official Regulatory Statement
Contraindicated Combinations Co-administration with Ergot Derivatives (e.g., Ergotamine) is strictly contraindicated due to the theoretical potential for ergotism. Co-administration with Pimozide is also prohibited in certain regulatory contexts due to the heightened risk of QT interval prolongation.
Pharmacokinetic Profile Azithromycin is officially documented as an inhibitor of P-glycoprotein and a weak inhibitor of the CYP3A4 enzyme. This mechanism may affect the plasma levels of co-administered P- gp substrate drugs.
Exposure Modification The HIV protease inhibitor Nelfinavir results in a formally documented increased Azithromycin serum concentration ( AUC and Cmax). The drug may also potentiate the effects of oral anticoagulants like Warfarin, necessitating careful monitoring.
Pharmacodynamic Risk Concurrent use with other drugs known to prolong the QT interval (such as Class IA and III antiarrhythmics) carries an increased risk of ventricular arrhythmias, including Torsades de Pointes.
Timing Requirements To prevent a documented reduction in the rate of absorption ( Cmax), Azithromycin must be administered at least 2 hours before or after antacids containing aluminum or magnesium. In patients with severe renal impairment ( GFR < 10 mL/ min), systemic exposure is officially increased due to reduced clearance.

The regulatory profile establishes specific constraints, including explicit contraindications and mandatory timing separation rules for antacids, along with cautionary notes regarding increased systemic exposure in patients with reduced renal function.

Advertisements

Mechanism of Action

The action of Зиромин (Azithromycin) is based on a dual mechanism targeting both the pathogen and the host's physiological response, resulting in a predictable and regulated effect profile.


Blocking Bacterial Protein Synthesis

This core domain explains how the drug halts microbial growth by physically targeting the 50S ribosomal subunit within the bacterial cell. By binding to this essential molecular machinery, Зиромин sterically blocks the pathway necessary for the bacteria to create its vital proteins, leading to the inhibition of propagation and a reduction in the overall microbial load.


Modulating Host Inflammatory Responses

This secondary domain involves the drug's activity on host immune cells (e.g., phagocytes), which actively transport the drug to local areas of inflammation and infection. Once concentrated, Зиромин acts as a modulator to dampen overactive inflammatory pathways, such as the signaling that produces certain pro-inflammatory cytokines. This mechanism contributes to the regulation of local inflammation and limits the physiological consequences of inflammation. This mechanism contributes to the modulation of the inflammatory cascade, thereby influencing the drug's effect profile.

Advertisements

Dosage and Administration Information

How to Use ZIROMIN (Azithromycin) — Administration Guidelines

This section details the methods, schedules, and conditions for using Azithromycin (e.g., Зиромин), describing the parameters for its administration.

Administration Scope

Feature Description
Route of Administration Oral (tablets, capsules, suspension) or Intravenous (IV) infusion only.
Dosing Frequency Once daily (qDay) is the standard schedule for all multi-day regimens.
Standard Regimens Total 1,500 mg can be given as 500 mg once daily for 3 days, OR 500 mg on Day 1 followed by 250 mg on Days 2-5 (a 5-day course).
Timing Relative to Meals Standard oral forms may be taken with or without food. Extended-release oral suspension must be taken on an empty stomach (1 hour before or 2 hours after a meal).

Procedural and Population Rules

Feature Description
Pediatric Dosing Dosing is calculated based on body weight (mg/kg) for children using the oral suspension. Tablets are unsuitable for children weighing less than 45 kg.
IV Administration The 500 mg dose is administered as an IV infusion over a period of at least 60 minutes. It is not administered as a rapid IV bolus or an intramuscular injection.
Missed Dose Rule A missed dose should be taken as soon as remembered. The subsequent dose should be taken at the next regularly scheduled time on the following day.

Connection to the Overall Use Protocol

Administration guidelines define the once-daily frequency and the total, finite duration of therapy (typically 3 or 5 days). The instructions address standardized absorption by linking the food requirement to the specific oral formulation and stipulate procedural constraints, such as the minimum IV infusion time, that apply regardless of the specific condition being addressed.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Зиромин (Azithromycin)


Evidence for Use in Acute Respiratory Infections

Research has explored Azithromycin in the context of acute respiratory conditions, specifically focusing on Community-Acquired Pneumonia (CAP) and Acute Exacerbations of Chronic Bronchitis (AECB). For CAP, studies primarily utilize Randomized Controlled Trials (RCTs) and large observational cohort studies comparing Azithromycin against other standard regimens. These investigations examined critical outcomes such as patient survival (all-cause mortality), clinical cure or failure endpoints, and the number of days spent in the hospital, detailing the clinical outcomes that researchers tracked. Findings from these studies describe patterns related to measured clinical cure rates and observation periods, often using short-term follow-up periods.

Evidence for Use in Acute Otitis Media

Azithromycin was studied for its use in acute otitis media (ear infection), with a primary focus on pediatric patients (children). The evidence is mainly derived from comparative RCTs where a short-course Azithromycin regimen was evaluated against longer courses of other antibiotics. Researchers examined key outcomes such as the achievement of clinical cure or failure endpoints and the rates of microbiological change in the common bacteria causing the infection. Specific regulatory documents note the need for continued monitoring of resistance patterns in the bacteria that commonly cause otitis media.


Research Gaps and What is Still Uncertain About Зиромин

While the volume of research is considerable, several uncertainties persist within the evidence landscape. A significant concern that studies monitored is the emergence of antimicrobial resistance globally, a pattern that was associated with the widespread use of Azithromycin and is a focus of ongoing research. Furthermore, the data describing the use of Azithromycin in chronic lung conditions are generally focused on short-term changes, meaning limited information for long-term outcomes is available, and certainty remains low regarding the durability of any observed effects after treatment is stopped. The research highlights what is known — and what is still uncertain—and does not determine whether an individual will respond similarly.

Key Studies & References

  1. Azithromycin: Drug Information (MedlinePlus)
  2. Long-term azithromycin for preventing exacerbations of chronic obstructive pulmonary disease: a meta-analysis
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Зиромин (FAQ)


Q: Does Зиромин start working immediately or does it take time to feel the effects?

Pharmacokinetic studies described in official documents indicate that the medicine concentrates extensively in body tissues, which is a key part of its effect profile. The concentration of the drug in the blood requires approximately five to seven days to reach a steady-state level. Steady-state concentrations, where the drug's activity is maximized, are typically achieved after this period of use.


Q: Are there any common over-the-counter supplements that should be avoided when using Зиромин?

Official information and regulatory guidelines recommend that any co-administered products, including over-the-counter medicines, supplements, and herbal remedies, be reviewed with a health professional before use. Regulatory information indicates that antacids containing aluminum or magnesium are known to reduce the drug's absorption rate. For this reason, official guidance stipulates a mandatory separation of at least two hours between taking the antacid and Azithromycin.


Q: How long does Зиромин typically stay in your system after you stop taking it?

Regulatory documents state that the drug has a long elimination phase, which is reflected in a reported average terminal half-life of 68 hours. This characteristic is what allows for the once-daily dosing and shorter overall treatment courses.


Q: If I accidentally miss a dose of Зиромин, what is the generally described approach in the patient leaflet?

Patient information sheets typically instruct that the missed dose should be taken immediately upon remembering it was forgotten. The person should then take the subsequent dose at the next regularly scheduled time on the following day.


Q: Are there any food restrictions mentioned in the official instructions for Зиромин?

The official product information states that standard oral forms of the medicine, such as tablets and standard oral suspension, may be taken with or without food. However, if a patient is using a specific extended-release oral suspension formulation, regulatory instructions indicate that it must be taken on an empty stomach.


Q: Is Зиромин known to interact with caffeine or alcohol?

There are no formal restrictions preventing the use of this medicine with alcohol, and regulatory descriptions do not indicate that alcohol reduces its effectiveness. However, official guidance notes that consuming alcohol may intensify certain possible side effects, such as headache or gastrointestinal upset. No specific warnings are generally given for caffeine consumption.


Q: Can a person allergic to penicillin or sulfa drugs take Зиромин?

Azithromycin, which is in the macrolide class, is often listed in clinical guidance as an alternative option for patients with known allergies to penicillin or sulfonamide (sulfa) antibiotics. This suggests that cross-reactivity between these different drug classes is not generally a concern.


Q: Is there a generic version of Зиромин available, and is it considered equivalent?

Yes, regulatory bodies have approved multiple generic versions of the active ingredient Azithromycin. These generic products are reviewed and determined by regulators to be bioequivalent, which is the regulatory finding used to support therapeutic equivalence to the original brand-name drug.


Q: Can Зиромин be taken alongside common pain relievers like ibuprofen or acetaminophen?

Official drug interaction databases do not typically report a direct interaction between Azithromycin and common, non-prescription pain relievers like ibuprofen or acetaminophen. Despite this, the use of any co-administered medicine should be reviewed by a health professional for guidance.


Q: Can Зиромин be taken by people who are sensitive to certain foods or dyes?

Official product information, such as the full label and package inserts, lists all inactive ingredients used in the medicine. This list includes excipients, colorants (dyes), and flavorings. This information is available to be checked for any known sensitivities or allergies.


Q: Is Зиромин safe to use for older adults (seniors)?

Pharmacokinetic studies indicate that drug concentrations in older men were similar to those in younger adults, but older women may have higher peak concentrations. General use is common, but official guidance advises special caution in older adults who have pre-existing cardiac risk factors or specific heart conditions.


Q: What is the risk of developing a long-term side effect from Зиромин?

For situations that involve long-term, non-acute use (such as prophylaxis in chronic lung conditions), studies have monitored the risk of developing antimicrobial resistance. Additionally, research has investigated observed changes in the composition of the gut microbiome associated with extended treatment.


Q: Is Зиромин available in different forms, such as liquid or chewable tablets?

The medicine is officially available as solid tablets for oral use, a powder that is mixed to create an oral suspension (liquid), and a sterile intravenous (IV) solution for injection. Chewable tablets are not typically listed among the officially approved forms.


Q: Why is it important to check for interactions before starting Зиромин?

Checking for interactions is crucial because the drug carries specific warnings against use with certain other medications. These interactions can lead to severe adverse events, such as ergotism, or potentially fatal, irregular heart rhythms.


Q: Has Зиромин been widely studied in children and teenagers?

Targeted studies have been conducted to establish specific dosing and use guidelines for various bacterial infections, such as acute otitis media and pharyngitis/tonsillitis, in pediatric patients. Safety and efficacy have been established for use in children aged six months and older for certain conditions.


Q: Can Зиромин be split or crushed to make it easier to take?

For certain dosage forms, such as capsules, patient instructions specifically state that the medicine should be swallowed whole and should not be cut, crushed, or broken. The oral suspension form is available for individuals who have difficulty swallowing tablets.


Q: Does taking Зиромин at a certain time of day influence its effectiveness?

Official instructions specify that the drug must be taken once daily. The standard dosing regimen is designed to ensure consistent drug concentrations throughout the day, and the specific time of day (morning or evening) the dose is taken is generally not a factor in its effectiveness.


Q: Are there specific symptoms that official guidelines recommend looking out for after starting Зиромин?

Official guidelines highlight specific symptoms that require immediate attention. These include the sudden onset of severe or bloody diarrhea (a potential sign of Clostridioides difficile-associated diarrhea), signs of liver problems (such as yellowing of the skin or eyes), and any symptoms indicative of a severe allergic reaction.


Q: Is Зиромин generally described as a prescription-only medicine?

Yes, official health databases and regulatory information consistently classify the active substance Azithromycin as a prescription-only medication for use against bacterial infections.


Q: Is it normal to feel a mild headache when first starting Зиромин?

Headache is listed in official documentation among the most commonly reported adverse reactions, typically observed with an incidence rate of 1% or greater. This means it is a known and relatively frequent occurrence when starting the drug.


Q: What information about liver health is important when considering Зиромин?

Official information notes that the drug has been associated with rare cases of acute liver injury, including fatal hepatic failure. Furthermore, a history of cholestatic jaundice or liver problems specifically associated with previous use of Azithromycin is listed as an absolute reason not to use the medicine.


Q: How is the safety profile of Зиромин summarized in official documents?

The official safety profile indicates that the most common adverse reactions are related to the gastrointestinal system, such as diarrhea and nausea. Clinically significant warnings involve the potential for heart rhythm risks (QT interval prolongation), liver injury (hepatotoxicity), and severe allergic reactions.


Q: What is the general guidance on stopping the use of Зиромин?

Official guidance emphasizes the importance of completing the full prescribed course of therapy to help prevent the development of drug-resistant bacteria. Official documentation notes that stopping the medication abruptly or early should be avoided, and that individuals should consult a health professional regarding the cessation of use.

Advertisements

How should Зиромин be stored and disposed of?

Зиромин (Azithromycin) must be handled and stored according to specific regulatory requirements to ensure its stability.

Storage Conditions

Item Requirement
Temperature Tablets and dry powder must be stored at controlled room temperature, typically not exceeding 30 C.
Protection Store in the original container, keep it tightly closed, and protect the medicine from excess heat, moisture, and light.
Liquid/Suspension The liquid oral suspension (reconstituted) is stable for a limited time, generally 10 days, and must be stored between 5 C and 30 C. Do not freeze the suspension.
Child Safety Keep the medicine out of the sight and reach of children at all times.

Disposal Instructions

Any unused or expired Зиромин must be disposed of according to local pharmaceutical waste requirements. Official guidance strongly recommends using drug take-back programs or authorized collection points for disposal. The medicine should not be flushed down a toilet or poured into a drain unless specifically instructed by governmental disposal guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Зиромин found in:

A-Z Index: